Genprex (NASDAQ:GNPX) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Genprex (NASDAQ:GNPX) in a research note released on Monday morning, Marketbeat.com reports. The brokerage currently has a $10.00 price objective on the stock. HC Wainwright also issued estimates for Genprex’s Q4 2023 earnings at ($5.39) EPS, FY2023 earnings at ($24.10) EPS, Q1 2024 earnings at ($3.37) EPS, Q2 2024 earnings at ($1.60) EPS, Q3 2024 earnings at ($1.18) EPS, Q4 2024 earnings at ($1.03) EPS and FY2024 earnings at ($5.85) EPS.

Genprex Price Performance

GNPX stock opened at $2.73 on Monday. The firm has a market cap of $4.07 million, a price-to-earnings ratio of -0.11 and a beta of -0.57. Genprex has a 1-year low of $2.50 and a 1-year high of $46.00. The firm has a fifty day moving average price of $5.32 and a two-hundred day moving average price of $9.32.

Hedge Funds Weigh In On Genprex

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Jane Street Group LLC acquired a new position in shares of Genprex during the third quarter valued at $28,000. Tower Research Capital LLC TRC boosted its stake in Genprex by 1,073.7% during the 3rd quarter. Tower Research Capital LLC TRC now owns 20,986 shares of the company’s stock valued at $30,000 after purchasing an additional 19,198 shares during the period. XTX Topco Ltd acquired a new position in Genprex during the 2nd quarter valued at about $38,000. Virtu Financial LLC grew its position in Genprex by 43.9% in the 2nd quarter. Virtu Financial LLC now owns 29,710 shares of the company’s stock worth $41,000 after purchasing an additional 9,069 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Genprex in the first quarter valued at approximately $68,000. 14.05% of the stock is currently owned by institutional investors and hedge funds.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) that is in Phase 1/2 and 2 clinical trials to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002 for the treatment of type 1 diabetes, and GPX-003 for the treatment of type 2 diabetes.